Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,753,526
  • Shares Outstanding, K 96,031
  • Annual Sales, $ 129,160 K
  • Annual Income, $ -36,240 K
  • 60-Month Beta 2.17
  • Price/Sales 13.52
  • Price/Cash Flow N/A
  • Price/Book 3.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.67
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -162.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.51 +25.81%
on 11/13/19
18.57 -1.67%
on 12/06/19
+2.00 (+12.30%)
since 11/06/19
3-Month
14.24 +28.23%
on 10/18/19
19.80 -7.78%
on 09/17/19
+0.70 (+3.99%)
since 09/06/19
52-Week
14.24 +28.23%
on 10/18/19
28.86 -36.74%
on 04/10/19
-0.68 (-3.59%)
since 12/06/18

Most Recent Stories

More News
Options Traders Expect Huge Moves in Denali (DNLI) Stock

Investors need to pay close attention to Denali (DNLI) stock based on the movements in the options market lately.

DNLI : 18.26 (+0.44%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 3.59 (-20.04%)
DNLI : 18.26 (+0.44%)
EVLO : 4.18 (-7.01%)
KLDO : 5.36 (-16.51%)
MRNA : 18.94 (-8.24%)
RUBY : 10.62 (+2.71%)
MCRB : 3.67 (-0.27%)
SYRS : 4.60 (-0.86%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 92.07 (+0.47%)
AXLA : 3.59 (-20.04%)
DNLI : 18.26 (+0.44%)
EVLO : 4.18 (-7.01%)
KLDO : 5.36 (-16.51%)
MRNA : 18.94 (-8.24%)
RUBY : 10.62 (+2.71%)
MCRB : 3.67 (-0.27%)
SYRS : 4.60 (-0.86%)
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 9.43% and 25.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 18.26 (+0.44%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -32.61% and -7.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 18.26 (+0.44%)
Denali Therapeutics is Now Oversold (DNLI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

DNLI : 18.26 (+0.44%)
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 18.26 (+0.44%)
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DNLI : 18.26 (+0.44%)
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 4050.00% and 1191.24%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the...

DNLI : 18.26 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade DNLI with:

Business Summary

Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO,...

See More

Key Turning Points

2nd Resistance Point 18.87
1st Resistance Point 18.56
Last Price 18.26
1st Support Level 17.96
2nd Support Level 17.67

See More

52-Week High 28.86
Fibonacci 61.8% 23.28
Fibonacci 50% 21.55
Fibonacci 38.2% 19.83
Last Price 18.26
52-Week Low 14.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar